PT  - JOURNAL ARTICLE
AU  - Connor Davis
AU  - Michael Gao
AU  - Marshall Nichols
AU  - Ricardo Henao
TI  - Predicting Hospital Utilization and Inpatient Mortality of Patients Tested for COVID-19
AID  - 10.1101/2020.12.04.20244137
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.04.20244137
4099  - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20244137.short
4100  - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20244137.full
AB  - Using structured elements from Electronic Health Records (EHR), we seek to: i) build predictive models to stratify patients tested for COVID-19 by their likelihood for hospitalization, ICU admission, mechanical ventilation and inpatient mortality, and ii) identify the most important EHR-based features driving the predictions. We leveraged EHR data from the Duke University Health System tested for COVID-19 or hospitalized between March 11, 2020 and August 24, 2020, to build models to predict hospital admissions within 4 weeks. Models were also created for ICU admissions, need for mechanical ventilation and mortality following admission. Models were developed on a cohort of 86,355 patients with 112,392 outpatient COVID-19 tests or any-cause hospital admissions between March 11, 2020 and June 4, 2020. The four models considered resulted in AUROC=0.838 (CI: 0.832-0.844) and AP=0.272 (CI: 0.260-0.287) for hospital admissions, AUROC=0.847 (CI: 0.839-855) and AP=0.585 (CI: 0.565-0.603) for ICU admissions, AUROC=0.858 (CI: 0.846-0.871) and AP=0.434 (CI: 0.403-0.467) for mechanical ventilation, and AUROC=0.0.856 (CI: 0.842-0.872) and AP=0.243 (CI: 0.205-0.282) for inpatient mortality. Patient history abstracted from the EHR has the potential for being used to stratify patients tested for COVID-19 in terms of utilization and mortality. The dominant EHR features for hospital admissions and inpatient outcomes are different. For the former, age, social indicators and previous utilization are the most important predictive features. For the latter, age and physiological summaries (pulse and blood pressure) are the main drivers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by NIH/NIBIB R01-EB025020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An exemption from institutional review board approval was determined by the DUHS Institutional Review Board as part of an active epidemiological investigation with no (current) medical intervention.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study is Protected Health Information and therefore cannot be shared publicly